241 related articles for article (PubMed ID: 32489980)
1. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
Piao J; Lim HJ; Lee M
Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
3. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis.
Wang YM; Cai W; Xue QM; Zhang JY; Zhou L; Xiong SY; Deng H
Front Immunol; 2023; 14():1234894. PubMed ID: 37654479
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
Xian F; Ren D; Bie J; Xu G
Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Cui Q; Li W; Wang D; Wang S; Yu J
World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
[TBL] [Abstract][Full Text] [Related]
8. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients.
Liu X; Shan C; Song Y; Du J
Front Oncol; 2019; 9():1111. PubMed ID: 31709181
[No Abstract] [Full Text] [Related]
10. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Wang Q; Liu F; Liu L
Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Wang L
J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
[TBL] [Abstract][Full Text] [Related]
12. A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients.
Yang J; Dong M; Shui Y; Zhang Y; Zhang Z; Mi Y; Zuo X; Jiang L; Liu K; Liu Z; Gu X; Shi Y
Cancer Cell Int; 2020; 20():96. PubMed ID: 32256205
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.
Zeng YF; Wei XY; Guo QH; Chen SY; Deng S; Liu ZZ; Gong ZC; Zeng WJ
Front Immunol; 2023; 14():1168244. PubMed ID: 37122727
[TBL] [Abstract][Full Text] [Related]
15. Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
Gu X; Dong M; Liu Z; Mi Y; Yang J; Zhang Z; Liu K; Jiang L; Zhang Y; Dong S; Shi Y
Cancer Cell Int; 2019; 19():146. PubMed ID: 31143091
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis.
Guo W; Wang P; Li N; Shao F; Zhang H; Yang Z; Li R; Gao Y; He J
Oncotarget; 2018 Mar; 9(17):13920-13933. PubMed ID: 29568405
[TBL] [Abstract][Full Text] [Related]
17. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis.
Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y
Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
Li J; Wang P; Xu Y
PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
Yang L; Xue R; Pan C
Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
[No Abstract] [Full Text] [Related]
20. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
